Log in to your Inderes Free account to see all free content on this page.
Enorama Pharma
0.50 SEK
-19.94 %
Less than 1K followers
ERMA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Enorama Pharma
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue | 7.6 | 2.1 | 11.0 | 6.9 | 1.4 | 15.8 |
| growth-% | -71.8 % | 414.3 % | -37.9 % | -80.1 % | 1,059.6 % | |
| EBITDA | -22.7 | -22.7 | -25.6 | -36.0 | -38.6 | -27.1 |
| EBIT | -22.9 | -23.0 | -26.9 | -39.5 | -42.1 | -47.5 |
| Profit before taxes | -23.8 | -23.5 | -27.7 | -40.1 | -44.6 | -43.8 |
| Net income | -23.8 | -23.5 | -27.7 | -40.1 | -44.6 | -43.8 |
| EPS | -3.65 | -3.28 | -2.98 | -3.54 | -0.90 | -0.72 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| EBITDA-% | -298.6 % | -1,057.3 % | -231.6 % | -525.3 % | -2,836.8 % | -171.9 % |
| EBIT-% | -300.6 % | -1,072.3 % | -244.1 % | -576.9 % | -3,097.8 % | -301.3 % |
| ROE | -331.5 % | -1,320.0 % | -129.9 % | -119.7 % | -228.3 % | -561.7 % |
| ROI | -55.9 % | -57.3 % | -54.5 % | -79.1 % | -129.7 % | -275.7 % |
Login required
This content is only available for logged in users